SINOVAC BIOTECH LTD
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- 850.08%
About Sinovac Biotech
Pharmaceutical Preparations, SIC 2834
Sinovac Biotech Ltd. is a biopharmaceutical company engaged in researching, developing, manufacturing, and commercializing human vaccines against infectious diseases. Its commercial product portfolio includes vaccines for hepatitis A, hepatitis B, enterovirus 71 hand-foot-and-mouth disease, seasonal influenza, poliomyelitis, pneumococcal disease, varicella, and tetanus. The company's customer base encompasses domestic private-pay consumers and public immunization programs in China, sovereign health systems, and international procurement organizations such as United Nations agencies.
The company operates corporate headquarters and production facilities in the Haidian District of Beijing, along with additional manufacturing and research bases in Beijing's Changping and Daxing districts, Dalian, and Chengdu, with a development site in Hangzhou. Internationally, it exports products to nearly eighty countries and maintains overseas operating subsidiaries in Bangladesh, Chile, Colombia, Indonesia, Mexico, the Philippines, and Thailand, alongside commercial partnerships and production joint ventures in Turkey and Colombia.
Summary of the business section of Sinovac Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SINOVAC BIOTECH LTD
- Founded
- 1999
- Headquarters
- Beijing, China
- Address
- No. 39 Shangdi Xi Road, Haidian District 100085
- Phone
- 86-10-82799800
- Website
- sinovac.com
- Employees
- 2,602, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- B9
- Fiscal year ends
- December 31
- Auditor
- Zhonghua Certified Public Accountants LLP, Shanghai, China
Stock & identifiers
- Ticker
- SVA
- Exchange
- Nasdaq
- Shares outstanding
- 72M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1084201
- CUSIP
- P8696W104
- ISIN
- USP8696W1047
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yin Weidong | Chief Executive Officer, Director | 6,359,500 |
| Guang (Helen) Yang | Chief Business Officer | 172,900 |
| Nan Wang | Chief Financial Officer | 355,000 |
| Jing (Nmn) Li | VP, Quality and Production | 227,500 |
| Qiang (Nmn) Gao | Chief Operation Officer | 230,000 |
| Jiaqiang Li | Director | 18,515,315 |
| Yuk Lam Lo | Director | 90,000 |
| Simon Anderson | Director | 70,000 |
| Yu Min Qiu | Director | – |
| Shan Fu | Director | 5,903,000 |
| Shuge Jiao | Director | – |
| Yu (Nmn) Wang | Director | – |
| Andrew Y. Yan | Director | 10,780,820 |
Employees
Headcount reported in annual reports
“We had 2,602 full-time employees as of December 31, 2025, and we depend to a great extent on principal members of our management and scientific teams.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 30, 2026 | Late filing | Notification of late filing |
| Apr 29, 2025 | Late filing | Notification of late filing |
| Jan 8, 2024 | Tender offer | Third-party tender offer for the company's shares |
| Aug 25, 2023 | Tender offer | Third-party tender offer for the company's shares |
| Feb 22, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 30, 2018 | Late filing | Notification of late filing |
| May 1, 2017 | Late filing | Notification of late filing |
| Mar 29, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 13, 2009 | Delisting | Notice of delisting from exchange (Form 25) |
| Nov 13, 2009 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 30, 2006 | Late filing | Notification of late filing |
| Dec 7, 2004 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 13, 2004 | Name change | Name changed from NET FORCE SYSTEMS INC to SINOVAC BIOTECH LTD |